U.S. Markets closed

Xencor Inc (XNCR) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Xencor Inc (XNCR) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Xencor Inc is engaged in the field of biotechnology. The United States-based firm develops drugs to combat severe diseases such as allergies and cancers. Xencor Inc has a market cap of $1.72 billion; its shares were traded at around $30.66 with and P/S ratio of 33.42.

For the last quarter Xencor Inc reported a revenue of $29.0 million, compared with the revenue of $0.00 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $40.6 million, an increase of 13.7% from last year. For the last five years Xencor Inc had an average revenue growth rate of 41% a year.

The reported loss per diluted share was $1.31 for the year. The Xencor Inc had an operating margin of -195.48%, compared with the operating margin of -149.99% a year before. The 10-year historical median operating margin of Xencor Inc is -103.42%. The profitability rank of the company is 2 (out of 10).

At the end of the fiscal year, Xencor Inc has the cash and cash equivalents of $26.2 million, compared with $16.5 million in the previous year. The company had no long term debt. Xencor Inc has a financial strength rank of 8 (out of 10).

At the current stock price of $30.66, Xencor Inc is traded at close to its historical median P/S valuation band of $29.69. The P/S ratio of the stock is 33.42, while the historical median P/S ratio is 32.34. The stock gained 4.89% during the past 12 months.

For the complete 20-year historical financial data of XNCR, click here.

This article first appeared on GuruFocus.